Recently, ADC (Antibody-Drug Conjugate) conferences have been held one after another, with major biotech companies competing to report their ADC pipelines. It is expected that 2024 will still be the main venue for ADCs. Developing an entry-level ADC seems not difficult, but evaluating the pharmacology and toxicology in the preclinical stage has become a top … Read more
Currently, there are 15 ADC drugs approved globally, among which 6 ADC drugs have been approved in China, namely Trastuzumab emtansine, Brentuximab vedotin, Trastuzumab deruxtecan, Vidofludimus, Gemtuzumab ozogamicin, and Sacituzumab govitecan. This article provides a brief summary based on the currently approved ADC drugs worldwide, the types of tumors they are suitable for, and how … Read more
In the early 20th century, Paul Ehrlich first proposed the famous “magic bullet” theory, suggesting that drugs could be developed to specifically target pathogenic structures without harming normal tissues and cells. Subsequently, the concept of antibody-drug conjugates (ADCs) was introduced, combining the target specificity of monoclonal antibodies with the anti-tumor properties of cytotoxic molecules. After … Read more
ADCs (Antibody-Drug Conjugates) and RDCs (Radionuclide Conjugates) are innovative drugs that have gained significant attention in recent years, demonstrating enormous potential in the field of oncology. They are referred to as the “magic bullets” of tumor-targeted therapy because they enable precise treatment while avoiding damage to normal cells. ADC drugs link antibodies with known effective … Read more
As of now, the toxicity and prevention measures of ADC in solid tumors are known as follows: ① The indications for ADCs are rapidly expanding, gradually shifting from late-stage to early-stage, and from single therapy to combination strategies. ② The toxicity characteristics of most ADCs are similar to the cytotoxicity of their payloads. ③ Certain … Read more
▎This article is contributed by Ying’en Biotech (slightly edited) Since the first antibody-drug conjugate (ADC) was approved for the treatment of acute myeloid leukemia in 2000, after more than twenty years of exploration and development, 14 ADC drugs have been successfully approved for clinical treatment of tumors. In August 2022, the FDA announced the accelerated … Read more
Introduction Antibody-drug conjugates (ADC) are comprised of monoclonal antibodies that target specific antigens linked to small molecule cytotoxic drugs via a linker, combining the powerful killing effects of traditional small molecule chemotherapy with the tumor-targeting properties of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (trade name: Mylotarg)) was approved for the treatment of CD33-positive acute … Read more
Last week, while introducing the “Breakthroughs and Innovations in Lung Cancer Treatment” from the “AACR 2021 Annual Report on Anti-Cancer Progress”（>> Click to review）, I mentioned a popular research topic—Antibody-Drug Conjugates (ADCs), which saw two new ADCs approved and two ADCs expanding their indications in 2021. Some readers expressed a desire to learn more about … Read more
The development of ADC drugs has not been smooth sailing, with nearly 100 years of history since the concept of the “magic bullet” was proposed, but ultimately, the clouds have parted to reveal the moon. DS8201 has redefined ADC, but it is not the end of ADC drugs, rather a new beginning. A comprehensive understanding … Read more
ADC Field Blooms, new technologies evolve like a rolling tide, propelling biomedicine into high-speed mode. This is the best of times. As early as the early 20th century, Paul Ehrlich first proposed the concept of “magic bullets”; however, the first ADC drug, Mylotarg® (gemtuzumab ozogamicin), was not approved until nearly a century later. Every cloud … Read more